2017-03-13,Heron Therapeutics To Present At The Oppenheimer 27th Annual Healthcare Conference
2017-02-28,Heron Therapeutics To Present At The 37th Annual Cowen And Company Healthcare Conference
2017-02-24,Heron Therapeutics Announces Inclusion Of SUSTOL® (Granisetron) Extended-Release Injection In NCCN® Antiemesis Guidelines
2017-02-23,Heron Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results And Recent Corporate Progress
2017-02-08,Heron Therapeutics To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-31,Heron Therapeutics Announces Underwriters' Exercise In Full Of Option To Purchase Additional Shares
2017-01-25,First Week of HRTX September 15th Options Trading
2017-01-19,Heron Therapeutics Announces Pricing Of Underwritten Public Offering Of Common Stock
2017-01-18,Heron Therapeutics Announces Proposed Public Offering Of Common Stock
2017-01-12,Heron Announces Submission Of CINVANTI™ NDA For The Prevention Of Chemotherapy-Induced Nausea And Vomiting (CINV)
2017-01-05,Heron Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference
2017-01-04,Heron Therapeutics Establishes Synergy Of Bupivacaine And Meloxicam With HTX-011 For Prevention Of Post-Operative Pain In Phase 2 Clinical Studies
2017-01-04,Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial Of HTX-011 In Abdominoplasty
2016-12-20,First Week Of HRTX February 2017 Options Trading
2016-11-29,Susan G. Komen® Joins Forces With Heron Therapeutics To Raise Awareness Of The Supportive Care Needs Of Patients With Breast Cancer
2016-11-08,Heron Therapeutics Reports Financial Results For The Three And Nine Months Ended September 30, 2016 And Recent Corporate Progress
2016-10-31,Heron Therapeutics is Now Oversold (HRTX)
2016-10-17,Commit To Buy Heron Therapeutics At $7.50, Earn 12.7% Using Options
2016-10-13,Short Interest Moves 18.5% Higher For HRTX
2016-09-09,Noteworthy Friday Option Activity: HRTX, AERI, UBNT
2016-09-08,Heron Therapeutics Announces Presentations Of Results From Phase 2 Clinical Trial Of HTX-011 In Hernia Repair At PAINWeek® 2016
2016-09-06,Here's Why Investors Should Steer Clear of Opioids
2016-08-29,Heron Therapeutics Announces Poster Presentations Of Data From Phase 2 Clinical Program For HTX-011 At PAINWeek® 2016
2016-08-12,Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta
2016-08-10,Bullish Two Hundred Day Moving Average Cross - HRTX
2016-08-10,Heron Therapeutics Announces U.S. FDA Approval Of SUSTOL® (granisetron) Extended-Release Injection For The Prevention Of Chemotherapy-Induced Nausea And Vomiting
2016-08-08,Heron Therapeutics Reports Second Quarter 2016 Financial Results And Recent Corporate Progress
2016-08-02,Heron Therapeutics Enters Into Loan Agreement For Up To $100 Million
2016-08-01,Notable Monday Option Activity: HRTX, SGMS, BSFT
2016-08-01,Heron Therapeutics Reports Positive Top-Line Results From Phase 2 Studies Of HTX-011 For Management Of Post-Operative Pain
2016-07-19,Noteworthy Tuesday Option Activity: HRTX, OMF, SCLN
2016-07-18,HRTX March 2017 Options Begin Trading
2016-07-08,Biotech Stock Mailbag: Heron, Exelixis
2016-06-27,First Week of August 19th Options Trading For Heron Therapeutics (HRTX)
2016-06-22,Heron Therapeutics Announces Appointment Of Christian Waage To Board Of Directors
2016-06-15,Heron Therapeutics To Present At The JMP Securities Life Sciences Conference
2016-05-18,Heron and the Never-Ending FDA Drug Review
2016-05-05,Heron Therapeutics Announces First Quarter 2016 Financial Results And Recent Corporate Progress
2016-04-18,Heron Therapeutics Provides Update On FDA Review Of SUSTOL® NDA
2016-04-11,Noteworthy Monday Option Activity: HRTX, Z, CLD
2016-03-23,First Week of HRTX May 20th Options Trading
2016-03-17,Heron Therapeutics Appoints David L. Szekeres, SVP Business Development, General Counsel And Corporate Secretary
2016-03-03,Heron Therapeutics Provides Update On SUSTOL® NDA
2016-02-29,Heron Therapeutics Provides Update On SUSTOL® NDA
2016-02-19,Heron Therapeutics Announces Fourth Quarter And Full Year 2015 Financial Results And Recent Corporate Progress
2016-02-04,Heron Therapeutics To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2016-01-28,Heron Therapeutics Appoints Kimberly J. Manhard As Executive Vice President Of Drug Development
2016-01-20,Oversold Conditions For Heron Therapeutics (HRTX)
2016-01-15,Heron Therapeutics Notified By FDA That It Will Not Take Action On SUSTOL® New Drug Application By The PDUFA Date
2016-01-05,Commit To Purchase Heron Therapeutics At $15, Earn 27.3% Using Options
2015-12-23,HERON THERAPEUTICS (HRTX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Heron Therapeutics, Inc. For Potential Securities Violations And Breach Of Fiduciary Duty
2015-11-10,Heron Therapeutics To Participate In Investor Conferences In November 2015
2015-11-06,Heron Therapeutics Announces Third Quarter 2015 Financial Results And Recent Corporate Progress
2015-10-12,Heron Therapeutics Appoints Neil J. Clendeninn, M.D., Ph.D. As Senior Vice President And Chief Medical Officer
2015-09-28,Heron Therapeutics Announces Oral Presentation Of Data From Completed Phase 3 MAGIC Study For SUSTOL® At The ASCO Breast Cancer Symposium
2015-09-22,Heron Therapeutics Reports Positive Top-Line Results From Phase 2 Study Of HTX-011 In The Management Of Post-Operative Pain
2015-09-22,Heron Therapeutics To Present Data From Completed Phase 3 MAGIC Study Of SUSTOL® At ASCO Breast Cancer Symposium
2015-09-18,Heron Therapeutics Announces FDA Acceptance Of New Drug Application For SUSTOL®
2015-08-07,Heron Therapeutics Announces Second Quarter 2015 Financial Results And Recent Corporate Progress
2015-07-20,Heron Therapeutics Resubmits SUSTOL® New Drug Application To FDA
2015-06-19,Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!
2015-06-16,Heron Therapeutics Initiates Phase 2 Clinical Trial Of HTX-011 For The Treatment Of Post-Operative Pain
2015-06-10,Heron Therapeutics (HRTX) Stock Spikes After Pricing Secondary Offering
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-01,New Cancer Therapy Study Results - MAGIC Trial
2015-05-28,Heron Therapeutics Announces Positive Results From Phase 3 MAGIC Study Of SUSTOL®
2015-05-26,Heron Therapeutics To Present At Investor Conferences In June 2015
2015-05-19,First Week Of HRTX July 17th Options Trading
2015-05-14,Heron Therapeutics Announces Positive Outcome From Meeting With FDA For HTX-019
2015-05-08,Heron Therapeutics Announces First Quarter 2015 Financial Results And Corporate Progress
2015-04-27,Heron Therapeutics To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference
2015-04-02,Heron Therapeutics Reaches Target Patient Enrollment In MAGIC Phase 3 Study Of SUSTOL®
2015-03-19,Heron Therapeutics Reports Positive Results From Phase 1 Study Of HTX-011
2015-03-13,Heron Therapeutics Announces Fourth Quarter And Full Year 2014 Financial Results And Corporate Progress
2015-02-23,Heron Therapeutics To Present At Upcoming Healthcare Conferences
2015-02-11,Heron Therapeutics Initiates Phase 1 Clinical Study Of HTX-011 For The Treatment Of Post-Operative Pain
2015-02-03,Heron Therapeutics To Present At The Leerink Partners 2015 Global Healthcare Conference
2015-01-21,Relative Strength Alert For Heron Therapeutics
2014-12-11,5 Stocks Under $10 Setting Up to Trade Higher: Covisint and More
2014-12-02,Heron Therapeutics To Present At The Oppenheimer 25th Annual Healthcare Conference
2014-11-06,Heron Therapeutics Discloses New Proprietary Intravenous Formulation Of NK-1 Receptor Antagonist For Prevention Of CINV
2014-11-06,Heron Therapeutics Announces Third Quarter And Year-to-Date 2014 Financial Results And Corporate Highlights
2014-10-08,Heron Therapeutics is Now Oversold (HRTX)
2014-08-25,Heron Therapeutics Appoints Esmé C. Smith As Vice President, General Counsel And Secretary
2014-08-04,Heron Therapeutics Announces Second Quarter And Year-to-Date 2014 Financial Results
2014-07-30,4 Stocks Under $10 Making Big Moves
2014-07-16,Heron Therapeutics Enters Oversold Territory (HRTX)
,
,
,
